SCI时时刷

search
Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy that is characterized by differentiation arrest a...
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
BackgroundNatural killer (NK) cells are highly effective in recognizing and eliminating virus-infected or malignant cells....
Cardiovascular toxicities associated with bispecific T-cell engager therapy
WHAT IS ALREADY KNOWN ON THIS TOPICWHAT THIS STUDY ADDSNearly one in five reported events with BTE therapies involved a CV...
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
WHAT IS ALREADY KNOWN ON THIS TOPICMonitoring ongoing responses and assessing the risk of relapse are novel challenges whe...
Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma
MethodsCohorts and patientsThirty-three a/mRCC cases treated with ICIs were from the discovery and validation cohort of Di...
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
IntroductionColorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide.1 Increasing numbers of...
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
BackgroundChimeric antigen receptor T cell (CAR T) therapy targeting B cell-lineage molecules such as CD19 and B-cell matu...
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells
IntroductionChimeric antigen receptor (CAR) T-cell therapy is capable of effective responses and durable remissions in pat...
Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer
IntroductionEsophageal cancer is a high-incidence and idiopathic tumor in China and is the seventh most common cancer and ...
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma
WHAT IS ALREADY KNOWN ON THIS TOPICThere is a crucial need to identify effective combinations of immune checkpoint inhibit...
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
WHAT IS ALREADY KNOWN ON THIS TOPICBlockade of immune checkpoint pathways using monoclonal antibodies has substantially im...
Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative
WHAT IS ALREADY KNOWN ON THIS TOPICTumor mutational burden (TMB) is a possible predictive biomarker for immune checkpoint ...
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer
IntroductionUrothelial cancer (UC) is the seventh most common cancer in the USA, with more than 80 000 cases predicted in ...
Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel
IntroductionFor over two decades, therapeutic developments for non-muscle invasive bladder cancer (NMIBC) remained stagnan...
Sulforaphane activates CD8+ T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis
IntroductionCancer is a major cause of morbidity and mortality worldwide.1 Despite hundreds of years of development, tradi...
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series
WHAT IS ALREADY KNOWN ON THIS TOPICManagement of treatment refractory immune-related adverse events is challenging and ass...
CARs are sharpening their weapons
Factors hindering CAR T-cell activity in the tumor microenvironmentChimeric antigen receptor (CAR) T-cell therapy has demo...